×
About 16,222 results

ALLMedicine™ Erythropoietin Center

Research & Reviews  7,909 results

High-dose regimens of hypomethylating agents promote transfusion independence in IPSS l...
https://doi.org/10.18632/aging.202767
Aging Wan Z, Han B

Apr 5th, 2021 - The hypomethylating agents (HMAs) azacytidine (AZA) and decitabine (DAC) are usually administered after the failure of erythropoietin-stimulating agents for lower-risk myelodysplastic syndromes (LR-MDS). However, it is unclear whether one of these...

Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
https://doi.org/10.1016/j.kint.2021.01.017
Kidney International; Pan SY, Tsai PZ et. al.

Apr 4th, 2021 - Prolyl hydroxylase domain enzyme (PHD) inhibitors are effective in the treatment of chronic kidney disease (CKD)-associated anemia by stabilizing hypoxia inducible factor (HIF), thereby increasing erythropoietin and consequently erythropoiesis. Ho...

Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not d...
https://doi.org/10.1016/j.kint.2021.03.019
Kidney International; Hanudel MR, Wong S et. al.

Apr 3rd, 2021 - Vadadustat is an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin production, and has been shown to decrease hepcidin levels, ameliorate iron restriction, and increase hemoglobin concen...

see more →

Guidelines  3 results

KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations ...
https://doi.org/10.1111/j.1440-1797.2011.01535.x
Nephrology (Carlton, Vic.); McMahon LP, MacGinley R et. al.

Nov 2nd, 2011 - KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents.|2011|McMahon LP,MacGinley R, ,|blood,etiology,therapy,therapeutic use,standards,analysis,standards,complica...

Removal of erythropoietin from anaemia trauma practice guideline does not increase red ...
https://doi.org/10.1016/j.injury.2009.06.007
Injury Christmas AB, Camp SM et. al.

Jul 14th, 2009 - We previously demonstrated that utilization of erythropoietin (r-EPO) did not significantly reduce blood utilization in trauma patients. We undertook this study to analyze blood utilization 1 year after r-EPO removal from our trauma service anaemi...

Is there a role for erythropoietin in neonatal medicine?
https://doi.org/10.1016/j.earlhumdev.2008.06.002
Early Human Development; Mainie P

Jul 25th, 2008 - Since it was first cloned in 1985, the therapeutic potential of recombinant human erythropoietin in the neonatal hyporegenerative anaemias has been studied-the anaemia of prematurity and haemolytic disease of the newborn. Between 60% and 100% of p...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  8,085 results

High-dose regimens of hypomethylating agents promote transfusion independence in IPSS l...
https://doi.org/10.18632/aging.202767
Aging Wan Z, Han B

Apr 5th, 2021 - The hypomethylating agents (HMAs) azacytidine (AZA) and decitabine (DAC) are usually administered after the failure of erythropoietin-stimulating agents for lower-risk myelodysplastic syndromes (LR-MDS). However, it is unclear whether one of these...

Kidney pericyte hypoxia-inducible factor regulates erythropoiesis but not kidney fibrosis.
https://doi.org/10.1016/j.kint.2021.01.017
Kidney International; Pan SY, Tsai PZ et. al.

Apr 4th, 2021 - Prolyl hydroxylase domain enzyme (PHD) inhibitors are effective in the treatment of chronic kidney disease (CKD)-associated anemia by stabilizing hypoxia inducible factor (HIF), thereby increasing erythropoietin and consequently erythropoiesis. Ho...

Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not d...
https://doi.org/10.1016/j.kint.2021.03.019
Kidney International; Hanudel MR, Wong S et. al.

Apr 3rd, 2021 - Vadadustat is an investigational hypoxia-inducible factor prolyl hydroxylase inhibitor that increases endogenous erythropoietin production, and has been shown to decrease hepcidin levels, ameliorate iron restriction, and increase hemoglobin concen...

see more →

News  223 results

Erythropoietin Falls Short of Neuroprotection in Optic Neuritis
https://www.medscape.com/viewarticle/946851

Mar 3rd, 2021 - Erythropoietin (EPO), shown in early studies to potentially provide neuroprotection for patients with optic neuritis, failed to provide any significant neuroprotection in comparison with placebo in a phase 3 randomized controlled trial. "EPO conve...

Fast Five Quiz: Iron Deficiency and Anemia in Heart Failure
https://reference.medscape.com/viewarticle/925290_3

May 11th, 2020 - ACE inhibitors, which may be prescribed in heart failure, have been shown to lead to a higher risk for anemia in patients with heart failure. Hemodilution is also considered to play a role in the development of anemia in heart failure; other poten...

Erythropoietin Fails to Stem Death, Neurodevelopmental Problems in Extreme Preemies
https://www.medscape.com/viewarticle/923849

Jan 15th, 2020 - (Reuters Health) - The hope that giving high-dose erythropoietin to extremely preterm infants would prevent death and neurodevelopment impairment appears to have dimmed. A new study of 941 infants born at 24 to just under 28 weeks of estimated ges...

Durable transfusion independence in MDS with imetelstat
https://www.mdedge.com/hematology-oncology/article/203102/myelodysplastic-syndrome/durable-transfusion-independence-mds?channel=253
Neil Osterweil

Jun 18th, 2019 - AMSTERDAM – For patients with low-risk myelodysplastic syndrome (MDS) for whom erythropoietin therapy has failed, the novel telomerase inhibitor imetelstat may provide long-lasting independence from transfusion, investigators reported. Neil Osterw.

CHMP supports expanded approval for epoetin alfa products
https://www.mdedge.com/hematology-oncology/article/184811/anemia/chmp-supports-expanded-approval-epoetin-alfa-products
HT Staff

Jul 31st, 2018 - Red blood cells The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended a change to the terms of marketing authorization for 3 versions of epoetin alfa—Abseamed, Binocrit, and Epoetin alfa Hexal. The C.

see more →

Patient Education  1 results see all →